Actively Recruiting
Evaluating 68Ga-FAPI Breast PETMRI Scans to Monitor Response to Chemotherapy in Invasive Breast Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-10-28
10
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the practicality of using a new imaging technique called 68Ga-FAPI PETMRI to see how well breast cancer responds to neoadjuvant chemotherapy. This study focuses on adults newly diagnosed with invasive breast cancer who have lymph node involvement and are planning to receive standard chemotherapy before surgery. The study is sponsored by Memorial Sloan Kettering Cancer Center and is designed as a phase 1 interventional trial. Participants will undergo three 68Ga-FAPI PETMRI scans during the study. These scans are performed to monitor the breast cancers response to chemotherapy. The study does not involve any comparison groups or masking. The imaging helps evaluate the extent of cancer and treatment effects before surgical removal. During the study, participants will be closely monitored to complete all three planned scans within up to one year. Researchers will assess the number of participants who can complete these scans. The study includes various assessments such as imaging procedures, performance status evaluations, and informed consent procedures. The total duration for participation depends on completing the scans and chemotherapy timeline.
CONDITIONS
Brief Title
A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer
Research Team
S
Somali Gavane, MD
R
Roberto Valentin, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here